Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control

Human Vaccines

Volumn 5, Issue 3, 2009, Pages 126-135

  Kreijtz, Joost H C M ^a   Osterhaus, Albert D M E ^a   Rimmelzwaan, Guus F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

H5N1; Influenza virus; Pandemic; Vaccine development; Vaccines

Indexed keywords

DNA VACCINE; FLAUD; HN PROTEIN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; ISCOM; LIVE VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG; VIROSOME VACCINE; VIRUS VECTOR;

ADJUVANT THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; CROSS REACTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PANDEMIC; REVIEW; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT; VIRUS STRAIN; VIRUS VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; BIOTECHNOLOGY; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 66749137687     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.3.6986     Document Type: Review

References (150)

1. Stohr K. Influenza - WHO cares. Lancet Infect Dis 2002; 2:517.
2. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook on influenza: Oxford: Blackwell Science 1998; 358-72.
3. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature 1997; 389:554.
4. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998; 279:393-6.
5. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351:472-7.
6. WHO. Cumulative number of confirmed human cases of avian influenza A/ (H5N1) Reported to WHO www.who.int/csr/disease/avian_influenza/country/ cases_table_2008_06_19/en/index.html. Accessed 2008.
7. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333-40.
8. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis 2007; 13:1348-53.
9. Kuiken T, Holmes EC, McCauley J, Rimmelzwaan GF, Williams CS, Grenfell BT. Host species barriers to influenza virus infections. Science 2006; 312:394-7.
10. WHO. Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. WHO 2008; 1-26.
11. WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines - www.who.int/csr/disease/avian_influenza/guidelines/ H5VaccineVirusUpdate20080214.pdf; 2008.
12. WHO. Recommended composition of influenza virus vaccines for use in the 2008-2009 influenza season www.who.int/csr/disease/influenza/ recommended_compositionFeb08Full-Report.pdf; 2008.
13. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004; 305:371-6.
14. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
15. Ada G. Overview of vaccines and vaccination. Mol Biotechnol 2005; 29:255-72.
16. Belshe RB, Walker R, Stoddard JJ, Kemble G, Maassab HF, Mendelman PM. Influenza vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines: Saunders Elsevier 2008; 291-309.
17. Keitel W, Piedra P. Live cold-adapted, reassortant influenza vaccines (USA). In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford: Blackwell Science 1998; 373-90.
18. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008.
19. Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, Stephenson I, et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 24:6588-93.
20. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23:66-72.
21. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136:168-75.
22. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7.
23. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2) and B viruses. Vaccine 1999; 18:899-906.
24. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002; 20:1340-53.
25. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
26. Suguitan AL, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, et al. Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets. PLoS Med 2006; 3.
27. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998; 252:324-30.
28. Wang X, Li M, Zheng H, Muster T, Palese P, Beg AA, et al. Influenza A virus NS1 protein prevents activation of NFkappaB and induction of alpha/ beta interferon. J Virol 2000; 74:11566-73.
29. Donelan NR, Basler CF, Garcia-Sastre A. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol 2003; 77:13257-66.
30. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with Reverse-Genetics-Produced H5N1 Influenza Vaccine Protects Ferrets against Homologous and Heterologous Challenge. J Infect Dis 2006; 194:159-67.
31. Lipatov AS, Webby RJ, Govorkova EA, Krauss S, Webster RG. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005; 191:1216-20.
32. Tian G, Zhang S, Li Y, Bu Z, Liu P, Zhou J, et al. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics. Virology 2005; 341:153-62.
33. Webster RG, Webby RJ, Hoffmann E, Rodenberg J, Kumar M, Chu HJ, et al. The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens. Virology 2006.
34. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003; 305:192-200.
35. de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, et al. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 2005; 79:12401-7.
36. Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004; 2:842-7.
37. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005; 23:2943-52.
38. EMEA. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application www.emea.europa.eu/pdfs/ human/vwp/471703en.pdf. London: EMEA 2004.
39. Patriarca PA. Use of Cell Lines for the Production of Influenza Virus Vaccines: An Appraisal of Technical, Manufacturing and Regulatory Considerations http://www.who.int/vaccine_research/diseases/influenza/ WHO_Flu_Cell_Substrate_Version3.pdf. Geneva, Switzerland: World Health Organization; 2007.
40. Genzel Y, Olmer RM, Schafer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 2006; 24:6074-87.
41. Palache AM, Scheepers HS, de Regt V, van Ewijk P, Baljet M, Brands R, et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand 1999; 98:115-25.
42. Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 2008; 26:3332-40.
43. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, Gerencer M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028-36.
44. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997; 16:312-22.
45. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999; 73:9679-82.
46. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-84.
47. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9:1909-17.
48. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001; 19:2716-21.
49. Toro H, Tang DC, Suarez DL, Zhang J, Shi Z. Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine. Vaccine 2008; 26:2640-6.
50. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 1999; 98:39-51.
51. Ghendon YZ, Markushin SG, Akopova II, Koptiaeva IB, Nechaeva EA, Mazurkova LA, et al. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine. Vaccine 2005; 23:4678-84.
52. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706-9.
53. Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, Limlamthong Y, et al. Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture. BMC Microbiol 2006; 6:16.
54. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 1999; 17:2265-74.
55. Possee RD. Cell-surface expression of influenza virus haemagglutinin in insect cells using a baculovirus vector. Virus Res 1986; 5:43-59.
56. Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999; 17:2073-80.
57. Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005; 339:273-80.
58. Huber VC, McCullers JA. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 2008; 10:75-85.
59. Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008; 10:56-61.
60. Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995; 171:1595-9.
61. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
62. Almeida JD, Edwards DC, Brand CM, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet 1975; 2:899-901.
63. Bron R, Ortiz A, Dijkstra J, Stegmann T, Wilschut J. Preparation, properties and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol 1993; 220:313-31.
64. Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005; 23:1232-41.
65. Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002; 20:2287-95.
66. de Mare A, Bungener LB, Regts J, de Vries-Idema J, van der Zee AG, Wilschut J, et al. The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity. Vaccine 2008; 26:2314-21.
67. Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344:160-3.
68. Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997; 15:1675-9.
69. Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 2001; 13:38-43.
70. de Bruijn IA, Nauta J, Gerez L, Palache AM. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects. Vaccine 2006; 24:6629-31.
71. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18:244-51.
72. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007; 81:3514-24.
73. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007; 25:3871-8.
74. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008; 3:1501.
75. Bridges CB, Katz J, Levandowski R, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines: Saunders Elsevier 2008; 259-90.
76. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 2008; 82:2565-9.
77. Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol 1968; 100:1139-40.
78. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007; 25:3554-60.
79. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-7.
80. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999; 73:5903-11.
81. De Swart RL, Kuiken T, Timmerman HH, van Amerongen G, Van Den Hoogen BG, Vos HW, et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 2002; 76:11561-9.
82. Polack FP. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 2007; 62:111-5.
83. O'Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 1997; 3:69-75.
84. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
85. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008; 180:5402-12.
86. Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM, et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 2001; 31:2910-8.
87. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998; 186:18-27.
88. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135-40.
89. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26:1525-9.
90. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17:3094-101.
91. Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005; 133:687-93.
92. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197-203.
93. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9.
94. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008; 3:1665.
95. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, et al. Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine. PLoS ONE 2008; 3:1401.
96. Rumke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88.
97. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308:457-60.
98. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000; 19:1180-7.
99. Rimmelzwaan GF, Osterhaus ADME. ISCOMs: Materials, preparation, antigen delivery and immune response. In: Gander B, Merkle HP, Corradin G, eds. Antigen delivery systems: Harwood Academic Publishers 1997; 123-38.
100. Rimmelzwaan GF, Osterhaust AD. Influenza vaccines: new developments. Curr Opin Pharmacol 2001; 1:491-6.
101. Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999; 17:1355-8.
102. Vogel FR, Hem SL. Immunologic adjuvants. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines: Saunders Elsevier 2008; 59-81.
103. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8.
104. Ulmer JB. Influenza DNA vaccines. Vaccine 2002; 20:74-6.
105. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9.
106. Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993; 11:957-60.
107. + T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998; 72:5648-53.
108. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002; 8:796-801.
109. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995; 1:583-7.
110. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, et al. Plasmid DNA-Based Vaccines Protect Mice and Ferrets against Lethal Challenge with A/Vietnam/1203/04 (H5N1) Influenza Virus. J Infect Dis 2008; 197:1643-52.
111. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization*. Annu Rev Immunol 2000; 18:927-74.
112. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24:4475-81.
113. Klinman DM, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G, et al. DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol 1997; 19:245-56.
114. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006; 344:230-9.
115. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007; 6:255-66.
116. Hoelscher MA, Jayashankar L, Garg S, Veguilla V, Lu X, Singh N, et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther 2007; 82:665-71.
117. Hoelscher MA, Singh N, Garg S, Jayashankar L, Veguilla V, Pandey A, et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 2008; 197:1185-8.
118. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367:475-81.
119. Holman DH, Wang D, Raja NU, Luo M, Moore KM, Woraratanadharm J, et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 2008; 26:2627-39.
120. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006; 80:1959-64.
121. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12:1032-40.
122. Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, et al. Recombinant Modified Vaccinia Virus Ankara-Based Vaccine Induces Protective Immunity in Mice against Infection with Influenza Virus H5N1. J Infect Dis 2007; 195:1598-606.
123. Kreijtz JHCM, Suezer Y, de Mutsert G, van den Brand JMA, van Amerongen G, Schnierle BS, et al. Recombinant modified vaccinia virus Ankara expressing HA confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2008; In press.
124. Mayr A, Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 1978; 41:225-34.
125. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001; 19:3700-9.
126. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79:347-52.
127. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004; 15:506-12.
128. Staib C, Drexler I, Sutter G. Construction and isolation of recombinant MVA. Methods Mol Biol 2004; 269:77-100.
129. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996; 397:7-13.
130. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992; 89:10847-51.
131. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003; 3:263-71.
132. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000; 74:7651-5.
133. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006; 12:3416-24.
134. Girard MP, Osterhaus A, Pervikov Y, Palkonyay L, Kieny MP. Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007. Vaccine 2008; 26:2443-50.
135. Weniger BG, Papania MJ. Alternative vaccine delivery methods. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines: Saunders Elsevier 2008; 1357-92.
136. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:59.
137. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, et al. Human infection with influenza H9N2. Lancet 1999; 354:916-7.
138. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363:587-93.
139. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 2004; 101:1356-61.
140. + T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999; 162:7578-83.
141. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008; 82:5161-6.
142. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-7.
143. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, Osterhaus AD, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007; 25:612-20.
144. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63.
145. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605.
146. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets and rhesus monkeys. Vaccine 2004; 22:2993-3003.
147. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13:426-35.
148. American Academy of Pediatrics Committee on Infectious D. Prevention of influenza: recommendations for influenza immunization of children, 2007-2008. Pediatrics 2008; 121:1016-31.
149. Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine 2007; 25:4983-4.
150. Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-41.